Pharmasyntez, a Russian biopharmaceutical company, has announced the launch of exports of its innovative drug Saterex to Uzbekistan.

The original drug Saterex has gained recognition within the medical community and is included in the List of Vital and Essential Drugs as well as the clinical guidelines of the Russian Ministry of Health, the Russian Association of Endocrinologists, and the Federal State Budget Institution National Medical Research Center for Endocrinology.

Saterex's competitive profile in the global market has been demonstrated through clinical trials and real-world practice among endocrinologists, placing it alongside medicinal products from leading international pharmaceutical companies.

“One of the Pharmasyntez Group’s top priorities is to bring our proprietary innovative drugs to global markets. Saterex is among the most advanced products in our portfolio, targeting one of the largest socially significant fields of endocrinology. Uzbekistan is the first CIS country to register and start importing this drug. This milestone marks a significant step toward expanding the company’s global footprint and strengthening its international presence,” said Nikita Punia, Executive Director of the Pharmasyntez Group.

Saterex's export highlights the importance of innovation in the Russian pharmaceutical industry, opens up new opportunities for the treatment of complex chronic diseases, and strengthens international medical collaboration.